Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | PDE6D | O43924 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259413 | 1.00 | HMGCR (0.56) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL3162910 | 0.93 | HMGCR (0.53) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL1978780 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL30799327 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL2050597 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL2050594 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL1978779 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL7933980 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL8239672 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL246624 | 0.92 | HMGCR (0.55) | HMGCRHDAC1HDAC2HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676729-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| US-9676729-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| US-9676729-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| US-9630906-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9630906-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9630906-B2 | Amine salts of pitavastatin and rosuvastatin | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2017-04-25 | — | — | US | disclosed |
| EP-2665722-B1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2016-08-17 | — | — | EP | disclosed |
| US-20160075664-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2016-03-17 | — | — | US | disclosed |
| US-20160075664-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2016-03-17 | — | — | US | disclosed |
| US-20160052864-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2016-02-25 | — | — | US | disclosed |
| US-8865900-B2 | Methyltetrazole sulfides and sulfones | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2014-10-21 | — | — | US | disclosed |
| US-8865900-B2 | Methyltetrazole sulfides and sulfones | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2014-10-21 | — | — | US | disclosed |
| WO-2014154856-A1 | AMINE SALTS OF PRAVASTATIN AND ROSUVASTATIN | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154857-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2014-10-02 | — | — | WO | disclosed |
| US-20130303779-A1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-11-14 | — | — | US | disclosed |
| US-20130303779-A1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-11-14 | — | — | US | disclosed |
| US-20130296563-A1 | METHYLTETRAZOLE SULFIDES AND SULFONES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-11-07 | — | — | US | disclosed |
| US-20130296563-A1 | METHYLTETRAZOLE SULFIDES AND SULFONES | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-11-07 | — | — | US | disclosed |
| US-20100274014-A1 | PROCESS FOR MANUFACTURING ROSUVASTATIN POTASSIUM AND CRYSTALLINE AND AMORPHOUS FORMS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | US | disclosed |
| US-20100274014-A1 | PROCESS FOR MANUFACTURING ROSUVASTATIN POTASSIUM AND CRYSTALLINE AND AMORPHOUS FORMS THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274014-A1 | PROCESS FOR MANUFACTURING ROSUVASTATIN POTASSIUM AND CRYSTALLINE AND AMORPHOUS FORMS THEREOF | PCSK9, HMGCR, PCSK6 | HMGCR 2/4885HDAC1 379/4885HDAC2 369/4885 |
| US-20130303779-A1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | STS, DHCR7, TST | HMGCR 5/4885HDAC1 2305/4885HDAC2 2291/4885 |
| US-20130296563-A1 | METHYLTETRAZOLE SULFIDES AND SULFONES | TST, STS, TPMT | HMGCR 6/4885HDAC1 919/4885HDAC2 1632/4885 |
| US-20160052864-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | HMGCR, PCSK9, COASY | HMGCR 1/4885HDAC1 1503/4885HDAC2 2085/4885 |
| US-20160075664-A1 | AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN | HMGCR, PCSK9, COASY | HMGCR 1/4885HDAC1 1361/4885HDAC2 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.